Table 1.
List of the Most Common Gene Modifications Related to CIN
| Chromosome Segregation Genes and Cell Cycle Genes Involved in CIN Cancers | Tumor Suppressor Genes or Oncogenes Involved in CIN Cancers | Gene Changes in CIN GC |
|---|---|---|
| PLK1 overexpression (proto-oncogene) | TP53 mutation (tumor suppressor) | AURKA (BTAK) overexpression (chromosome segregation regulation) |
| AURKA (BTAK) and AURKB overexpression | MET overexpression (proto-oncogene) | APC mutation (tumor suppressor) |
| BUB1/BUB3/BUB1B overexpression | RB1 mutation (tumor suppressor) | EGFR/HER2/ERBB2 overexpression (proto-oncogene) |
| MAD1/MAD2/MAD3 (BUBR1) overexpression | RAS (KRAS) overexpression (proto-oncogene) | RAS (KRAS and NRAS) overexpression (proto-oncogene) |
| ZWINT overexpression | ERBB2(HER2/neu/EGFR) overexpression (proto-oncogene) | MYC overexpression (proto-oncogene) |
| hZw10, hZwilch, and hRod mutations | FOXM1 overexpression (proto-oncogene) | CCNE1, CCND1, CDK6 overexpression (cell cycle–related genes) |
| NEK2 and MPS1 (TTK) overexpression | MYC overexpression (proto-oncogene) | MET overexpression (proto-oncogene) |
| CCNA2 (cyclin A2)/CCNB1 (cyclin-B1)/CCNB2/CCNE1/CCND1 overexpression | MDM2 overexpression (proto-oncogene) | TP53 mutation (tumor suppressor) |
| CDK1(CDC2)/CDK4 overexpression | BIRC5 (survivin) overexpression (proto-oncogene) | FGFR2 overexpression |
| CDC20 overexpression | VEGFA overexpression |
The table includes gene modifications in various cancers and the gene modifications detected in CIN GC up to present.